Orphan medicinal products in Europe;Les médicaments orphelins en Europe

Medecine/Sciences

Volumn 21, Issue SPEC. ISS. NOV., 2005, Pages 66-68

  Héron, Emmanuel ^a  

^a CENTRE HOSPITALIER NATIONAL D OPHTALMOLOGIE DES QUINZE VINGTS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANAGRELIDE; ARSENIC TRIOXIDE; BOSENTAN; BUSULFAN; CARGLUMIC ACID; CELECOXIB; CLADRIBINE; DUDOPA; FABRIZYME; IBUPROFEN; ILOPROST; IMATINIB; IMPAVIDA; LARONIDASE; LITAK; MITOTANE; NITISINONE; ORPHAN DRUG; PHOTOFRIN; PRIGIT; SOMOVERT; UNCLASSIFIED DRUG; WILZIN; ZAVESCO; ZINC ACETATE;

CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; DRUG RESEARCH; EUROPE; FABRY DISEASE; GAUCHER DISEASE; HUMAN; LAW; PREVALENCE; PROMYELOCYTIC LEUKEMIA; PULMONARY HYPERTENSION; THROMBOCYTHEMIA; TREATMENT OUTCOME; TYROSINEMIA; WILSON DISEASE;

EID: 29944434092     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (2)

1. Regulation (EC) NO 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products, 2000, OJ, L018, 1-5.
2. COMP Report to the Commission in Relation to article 10 of Regulation 141/2000 on Orphan Medicinal Products (July 2005). www.emea.eu.int